Guillain-Barre Syndrome (GBS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Guillain-Barre Syndrome

MalaCards integrated aliases for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 11 19 42 58 53 41 43 14 16 71
Guillain-Barré Syndrome 19 42 52 75 2 31
Acute Inflammatory Polyneuropathy 19 42 58
Gbs 19 42 58
Acute Inflammatory Demyelinating Polyradiculoneuropathy 19 58
Acute Inflammatory Demyelinating Polyneuropathy 19 71
Guillain-Barre Syndrome, Acute Inflammatory Demyelinating Polyradiculoneuropathic Form 58
Gbs, Acute Inflammatory Demyelinating Polyradiculoneuropathic Form 58
Acute Inflammatory Demyelinating Polyradiculopathy 11
Acute Idiopathic Demyelinating Polyneuropathy 58
Acute Autoimmune Peripheral Neuropathy 19
Landry-Guillain-Barre-Strohl Syndrome 19
Acute Immune-Mediated Polyneuropathy 19
Acute Postinfectious Polyneuropathy 11
Variant of Guillain-Barre Syndrome 58
Guillain-Barré-Strohl Syndrome 19
Landry-Guillain-Barre Syndrome 42
Guillain-Barre-Strohl Syndrome 58
Acute Inflammatory Neuropathy 19
Acute Infectious Polyneuritis 42
Acute Infective Polyneuritis 11
Post-Infectious Polyneuritis 11
Landry's Ascending Paralysis 19
Postinfectious Polyneuritis 11
Post-Infective Polyneuritis 19
Miller Fisher Syndrome 71
Infectious Neuronitis 11
Fisher Syndrome 42
Variant of Gbs 58
Aidp 58



Guillain-Barre Syndrome: Multigenic/multifactorial 58
Acute Inflammatory Demyelinating Polyradiculoneuropathy: Multigenic/multifactorial 58
Variant of Guillain-Barre Syndrome: Multigenic/multifactorial 58


Guillain-Barre Syndrome: 1-9/100000 (Worldwide, United States, Europe, France) 1-5/10000 (Denmark, Egypt) 58
Acute Inflammatory Demyelinating Polyradiculoneuropathy: 1-9/100000 (Europe) 58

Age Of Onset:

Guillain-Barre Syndrome: All ages 58
Acute Inflammatory Demyelinating Polyradiculoneuropathy: All ages 58
Variant of Guillain-Barre Syndrome: All ages 58


Orphanet: 58  
Rare neurological diseases

External Ids:

Disease Ontology 11 DOID:12842
MeSH 43 D020275
NCIt 49 C116345
SNOMED-CT 68 155082001
ICD10 31 G61.0
MESH via Orphanet 44 D020275
ICD10 via Orphanet 32 G61.0
UMLS via Orphanet 72 C0018378 C1963929
UMLS 71 C0018378 C0393799 C3542501

Summaries for Guillain-Barre Syndrome

MedlinePlus Genetics: 42 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations.Muscle weakness or paralysis are the characteristic features of Guillain-Barré syndrome. The weakness often begins in the legs and spreads to the arms, torso, and face and is commonly accompanied by numbness, tingling, or pain. Additional signs and symptoms of the condition include difficulty swallowing and difficulty breathing. Occasionally, the nerves that control involuntary functions of the body such as blood pressure and heart rate are affected, which can lead to fluctuating blood pressure or an abnormal heartbeat (cardiac arrhythmia).There are several types of Guillain-Barré syndrome, classified by the part of the peripheral nerve involved in the condition. The most common type of Guillain-Barré syndrome is acute inflammatory demyelinating polyradiculoneuropathy (AIDP). In AIDP, the immune response damages myelin, which is the covering that protects axons and promotes the efficient transmission of nerve impulses. In two other types of Guillain-Barré syndrome, acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), the axons themselves are damaged by the immune response. In AMAN, only the axons of motor neurons are damaged. In AMSAN, the axons of sensory neurons are also damaged. Because of sensory nerve damage, affected individuals can lose the ability to sense the position of their limbs and can have abnormal or absent reflexes (areflexia).Miller Fisher syndrome, another type of Guillain-Barré syndrome, involves cranial nerves, which extend from the brain to various areas of the head and neck. Miller Fisher syndrome is characterized by three features: weakness or paralysis of the muscles that move the eyes (ophthalmoplegia), problems with balance and coordination (ataxia), and areflexia. People with this condition can have other signs and symptoms common in Guillain-Barré syndrome, such as muscle weakness.Guillain-Barré syndrome occurs in people of all ages. The development of the condition usually follows a pattern. Prior to developing the condition, most people with Guillain-Barré syndrome have a bacterial or viral infection. The first phase of Guillain-Barré syndrome, during which signs and symptoms of the condition worsen, can last up to four weeks, although the peak of the illness is usually reached in one to two weeks. During the second phase, called the plateau, signs and symptoms of Guillain-Barré syndrome stabilize. This phase can last weeks or months. During the recovery phase, symptoms improve. However, some people with Guillain-Barré syndrome never fully recover and can still experience excessive tiredness (fatigue), muscle weakness, or muscle pain.

MalaCards based summary: Guillain-Barre Syndrome, also known as guillain-barré syndrome, is related to chronic inflammatory demyelinating polyradiculoneuropathy and miller fisher syndrome, and has symptoms including tremor, back pain and ophthalmoplegia. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Cytokine Signaling in Immune system and IL-9 Signaling Pathways. The drugs Eculizumab and Complement System Proteins have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and heart, and related phenotypes are acute demyelinating polyneuropathy and hyporeflexia

NINDS: 52 Guillain-Barré syndrome (GBS) is a rare neurological disorder in which the body's immune system attacks part of the peripheral nervous system. It is one of several disorders involving weakness due to peripheral nerve damage caused by the person's immune system. Initial symptoms include unexplained sensations such as tingling in the feet or hands, or pain, followed by weakness on both sides of the body. The weakness can increase in intensity over a period of hours to days to weeks until the muscles cannot be used at all and the person is almost totally paralyzed. If breathing muscles are affected, the person is often put on a ventilator. Most individuals, however, have good recovery from even the most severe cases of GBS, although some continue to have some degree of weakness. The exact cause of Guillain-Barré syndrome is unknown. It can occur a few days or weeks after the person has had symptoms of a respiratory or gastrointestinal viral infection. Occasionally, surgery will trigger the syndrome. In rare instances, vaccinations may increase the risk of GBS. Recently, some countries worldwide have reported an increased incidence of GBS following infection with the Zika virus. A nerve conduction velocity (NCV) test, which measures the nerve's ability to send a signal, can aid the diagnosis. The cerebrospinal fluid that bathes the spinal cord and brain contains more protein than usual in someone with GBS, so a physician may decide to perform a spinal tap to obtain a sample of fluid to analyze.

MedlinePlus: 41 Guillain-Barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (PNS). The PNS nerves connect your brain and spinal cord with the rest of your body. Damage to these nerves makes it hard for them to transmit signals. As a result, your muscles have trouble responding to your brain. No one knows what causes the syndrome. Sometimes it is triggered by an infection, surgery, or a vaccination. The first symptom is usually weakness or a tingling feeling in your legs. The feeling can spread to your upper body. In severe cases, you become almost paralyzed. This is life-threatening. You might need a respirator to breathe. Symptoms usually worsen over a period of weeks and then stabilize. Guillain-Barre can be hard to diagnose. Possible tests include nerve tests and a spinal tap. Most people recover. Recovery can take a few weeks to a few years. Treatment can help symptoms, and may include medicines or a procedure called plasma exchange. NIH: National Institute of Neurological Disorders and Stroke

GARD: 19 Guillain-Barré syndrome (GBS) is a rare syndrome in which the body's immune system attacks part of the peripheral nervous system. The peripheral nervous system carries signals from the brain to the muscles. Symptoms of GBS include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all (paralysis). The exact cause of Guillain-Barré syndrome is unknown. In most cases, GBS occurs a few days or weeks after symptoms of a viral infection. In rare cases, GBS may run in families. A diagnosis of GBS is suspected when a person has symptoms suggestive of the syndrome. A variety of tests, including a spinal tap, may be completed to confirm the diagnosis.

Orphanet 58 Guillain-barre syndrome: A clinically heterogeneous spectrum of rare post-infectious neuropathies that usually occur in otherwise healthy patients and encompasses acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS) and some other regional variants.

Acute inflammatory demyelinating polyradiculoneuropathy: A rare inflammatory neuropathy belonging to the clinical spectrum of Guillain-Barré syndrome (GBS).

CDC: 2 Guillain-Barré (Ghee-YAN Bah-RAY) syndrome (GBS) is a rare, autoimmune disorder in which a person's own immune system damages the nerves, causing muscle weakness and sometimes paralysis. GBS can cause symptoms that last for a few weeks to several years. Most people recover fully, but some have permanent nerve damage. Some people have died of GBS.

Disease Ontology: 11 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

Wikipedia: 75 Guillain-Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the... more...

Related Diseases for Guillain-Barre Syndrome

Diseases in the Guillain-Barre Syndrome family:

Guillain-Barre Syndrome, Familial

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1138)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyradiculoneuropathy 32.7 PMP22 MPZ MBP
2 miller fisher syndrome 32.7 TNF MOG ALB
3 polyneuropathy 31.8 PMP22 MPZ MBP ALB
4 bell's palsy 31.5 TNF MBP ALB
5 respiratory failure 31.3 TNF IL17A ICAM1 ALB
6 poliomyelitis 31.2 TNF ICAM1 ALB
7 myasthenia gravis 31.1 TNF MBP HLA-DRB1 HLA-DQB1
8 viral infectious disease 31.1 TNFRSF1A TNF IL17A ICAM1
9 purpura 31.0 TNF IL17A HLA-DRB1
10 demyelinating polyneuropathy 31.0 TNF PMP22 MPZ MOG MBP ALB
11 peripheral nervous system disease 31.0 TNF PMP22 PMP2 MPZ MOG MBP
12 mumps 31.0 TNFRSF1A TNF HLA-DRB1 HLA-DQB1
13 facial paralysis 30.9 TNF MOG MBP ALB
14 lyme disease 30.9 TNF IL17A HLA-DRB1 HLA-DQB1
15 exanthem 30.9 TNF IL17A ALB
16 hepatitis a 30.9 TNF HLA-DRB1 ALB
17 polyarteritis nodosa 30.8 TNF ICAM1 HLA-DRB1
18 membranous nephropathy 30.8 HP HLA-DQA1 ALB
19 reactive arthritis 30.8 TNF IL17A HP
20 plasmodium falciparum malaria 30.8 TNF ICAM1 HP
21 hereditary neuropathies 30.8 PMP22 MPZ
22 chickenpox 30.8 TNF MOG IL17A ALB
23 mononeuropathy 30.7 TNF PMP22 MPZ ALB
24 churg-strauss syndrome 30.7 TNF IL17A HLA-DRB1
25 polyradiculoneuropathy 30.7 TNFRSF1A PMP22 PMP2 MPZ MBP IL17A
26 sensory peripheral neuropathy 30.7 PMP22 MPZ ALB
27 cranial nerve palsy 30.7 TNF MOG ALB
28 spondyloarthropathy 1 30.7 TNFRSF1B TNFRSF1A TNF IL17A HP
29 severe cutaneous adverse reaction 30.7 TNF HLA-DRB1 HLA-DQB1
30 ileus 30.7 TNF IL17A ICAM1
31 diabetic neuropathy 30.7 PMP22 MPZ ALB
32 critical illness polyneuropathy 30.7 TNF ALB
33 headache 30.6 TNF HLA-DQB1 ALB
34 thyroiditis 30.6 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
35 transverse myelitis 30.6 TNF MOG MBP HLA-DRB1
36 arachnoiditis 30.6 TNF MBP
37 meningitis 30.6 TNF IL17A ICAM1 ALB
38 henoch-schoenlein purpura 30.6 TNF ICAM1 ALB
39 severe covid-19 30.6 TNF IL17A ALB
40 aphthous stomatitis 30.6 TNF IL17A ALB
41 common variable immunodeficiency 30.6 TNFRSF1B TNF HLA-DRB1 HLA-DQB1
42 leishmaniasis 30.6 TNFRSF1A TNF IL17A ALB
43 leprosy 3 30.5 TNF IL17A HLA-DRB1 HLA-DQA1 ALB
44 pulmonary tuberculosis 30.5 TNF HP HLA-DRB1 HLA-DQB1 ALB
45 acute disseminated encephalomyelitis 30.5 MOG MBP HCRT
46 spondylitis 30.5 TNFRSF1A TNF IL17A HLA-DRB1
47 myelitis 30.5 TNFRSF1A TNF MOG MBP IL17A
48 visceral leishmaniasis 30.5 TNF IL17A HLA-DRB1 HLA-DQB1 ALB
49 typhoid fever 30.5 TNFRSF1A TNF HLA-DRB1 HLA-DQB1 ALB
50 roussy-levy hereditary areflexic dystasia 30.5 PMP22 MPZ

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:

Diseases related to Guillain-Barre Syndrome

Symptoms & Phenotypes for Guillain-Barre Syndrome

Human phenotypes related to Guillain-Barre Syndrome:

58 30 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 acute demyelinating polyneuropathy 58 30 Obligate (100%) Obligate (100%)
2 hyporeflexia 58 30 Frequent (33%) Frequent (79-30%)
3 distal lower limb muscle weakness 58 30 Frequent (33%) Frequent (79-30%)
4 generalized hypotonia 58 30 Frequent (33%) Frequent (79-30%)
5 unsteady gait 58 30 Frequent (33%) Frequent (79-30%)
6 recurrent fever 58 30 Frequent (33%) Frequent (79-30%)
7 impaired oropharyngeal swallow response 58 30 Frequent (33%) Frequent (79-30%)
8 dysesthesia 58 30 Frequent (33%) Frequent (79-30%)
9 drooling 58 30 Frequent (33%) Frequent (79-30%)
10 emg: neuropathic changes 58 30 Frequent (33%) Frequent (79-30%)
11 sleepy facial expression 58 30 Frequent (33%) Frequent (79-30%)
12 onion bulb formation 58 30 Occasional (7.5%) Occasional (29-5%)
13 gait ataxia 58 Excluded (0%)

UMLS symptoms related to Guillain-Barre Syndrome:

tremor; back pain; ophthalmoplegia; headache; syncope; pain; chronic pain; sciatica; seizures; vertigo/dizziness; sleeplessness; cerebellar ataxia; neuralgia

GenomeRNAi Phenotypes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 ALB DAAM2 FCHO1 GALE HCRT HLA-DQA1
2 no effect GR00402-S-2 10.13 ALB DAAM2 FCHO1 GALE HLA-DQA1 HLA-DRB1

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.15 HCRT HLA-DQB1 ICAM1 MBP MOG MPZ
2 homeostasis/metabolism MP:0005376 10.13 ALB DAAM2 HCRT HLA-DQB1 HP ICAM1
3 muscle MP:0005369 10.06 ALB DAAM2 HCRT HLA-DQB1 ICAM1 MOG
4 growth/size/body region MP:0005378 9.97 DAAM2 HCRT HLA-DQB1 HLA-DRB1 ICAM1 IL17A
5 immune system MP:0005387 9.77 ALB DAAM2 HLA-DQA1 HLA-DQB1 HP ICAM1
6 hematopoietic system MP:0005397 9.4 DAAM2 HLA-DQA1 HLA-DQB1 HP ICAM1 IL17A

Drugs & Therapeutics for Guillain-Barre Syndrome

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Eculizumab Approved, Investigational Phase 3 219685-50-4
2 Complement System Proteins Phase 3
3 Immunosuppressive Agents Phase 3
4 Pharmaceutical Solutions Phase 2, Phase 3
Dalfampridine Approved Phase 2 504-24-5 1727
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
Licorice Approved Phase 1, Phase 2
Turmeric Approved, Experimental, Investigational Phase 1, Phase 2
9 Potassium Channel Blockers Phase 2
10 Antineoplastic Agents, Hormonal Phase 2
11 Hormones Phase 2
12 Hormone Antagonists Phase 2
13 glucocorticoids Phase 2
14 Anti-Inflammatory Agents Phase 2
15 Immunoglobulin G Phase 2
16 Astragalus Phase 1, Phase 2
17 Skullcap Phase 1, Phase 2
18 Turmeric extract Phase 1, Phase 2
19 Hawthorn Phase 1, Phase 2
20 Chinese Yam Phase 1, Phase 2
21 Chinese Salvia Phase 1, Phase 2
22 Chinese Rhubarb Phase 1, Phase 2
Sodium citrate Approved, Investigational 68-04-2 23431961
Caffeine Approved 58-08-2 2519
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
Tryptophan Approved, Nutraceutical, Withdrawn 73-22-3 6305
27 Hemostatics
28 Respiratory System Agents
29 Citrate
30 Central Nervous System Stimulants
31 Neurotransmitter Agents
32 Phosphodiesterase Inhibitors
33 Calcium, Dietary
34 Autoantibodies
35 Vaccines
36 Pyruvate
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Prospective, Multicenter, Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Eculizumab in Patients With Guillain-Barré Syndrome (GBS) Completed NCT04752566 Phase 3 Placebo
2 IVIG Versus Plasmapheresis and Guillian Barrie Syndrome Completed NCT05104762 Phase 2, Phase 3 Intravenous immunoglobulin
3 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
4 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
5 A Randomized, Double-blind, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré Syndrome Recruiting NCT04701164 Phase 2, Phase 3 ANX005;Placebo
6 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Patients With Guillain-Barré Syndrome Withdrawn NCT05494619 Phase 3 Crovalimab;Placebo;Intravenous immunoglobulin therapy
7 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
8 Assessment of Chronic GBS Improvement With Use of 4-AP Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
9 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome Patients in Bangladesh: A Safety and Feasibility Study Completed NCT02780570 Phase 2
10 Efficacy and Safety of Preventive Mechanical Ventilation in Adults With Guillain Barré Syndrome Completed NCT00167622 Phase 2
11 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone
13 An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients Recruiting NCT03943589 Phase 2 Imlifidase
14 Treating Sequalae Caused by Post-acute Sequelae of SARS (Severe Acute Respiratory Syndrome)-CoV-2 Infection Recruiting NCT04846010 Phase 1, Phase 2
15 A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome Completed NCT04035135 Phase 1 ANX005;Intravenous immunoglobulin
16 Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS) Not yet recruiting NCT03773328 Phase 1
17 Early Prediction of Respiratory and Autonomic Complications of GBS Using Neuromuscular Ultrasound Unknown status NCT04166357
18 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
19 Neuromuscular Ultrasound Changes in Neuropathies in Correlation to Neurophysiological Findings Unknown status NCT04092140
20 A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement Unknown status NCT03801135 Fibrinogen concentrate
21 Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Guillain-Barré Syndrome Unknown status NCT04550611
22 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
23 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
24 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
25 Assessment of Diaphragm Thickness by Ultrasonography in Guillain Barre Syndrome and Myasthenia Gravis Completed NCT05324176
26 Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome. Completed NCT01024088
27 Comparison of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Mechanically Ventilated Children With Guillain Barre Syndrome. A Randomized Study. Completed NCT01306578 IVIG
28 Neurology Inpatient Clinical Education Trial Completed NCT03826056
29 Risk of Guillain-Barré Syndrome Following Meningococcal Conjugate (MCV4) Vaccination Completed NCT00575653
30 An Assistive Powered Wheelchair: Stage 2 Trial - Powered Wheelchair User Evaluation of an Obstacle Alerting System. A Non-interventional Study Completed NCT05292690
31 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Completed NCT03206541
32 A Feasibility Study for Daily Use of a Brain Computer Interface for Communication in an ICU Completed NCT01005524
33 Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome Completed NCT04927598
34 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Completed NCT03941184
35 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200
36 The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat) Completed NCT03710278
37 Recovery of Visual Acuity in Vestibular Deficits Completed NCT00411216
38 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome : A Randomized Controlled Trial Completed NCT02883270
39 An Observational Cohort Study on the Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome Recruiting NCT04303962
40 Comparison of Effects of Proprioceptive Neuromuscular Training on Sensory Versus Motor Function in Patients With Guillain Barre Syndrome Recruiting NCT05491096
41 New Biomarkers in Acute and Chronic Inflammatory Demyelinating Polyradiculoneuropathies Recruiting NCT04249752
42 Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome (FOCUS on GBS) Recruiting NCT04829526
43 Genomics of COVID-19 Vaccine-induced Adverse Events (Guillain-Barré Syndrome [GBS], Vaccine-induced Immune Thrombotic Thrombocytopenia [VITT]/Thrombosis With Thrombocytopenia Syndrome [TTS], and Myocarditis/Pericarditis) Recruiting NCT05212792
44 Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS) Recruiting NCT04871035
45 National Vaccine Adverse Event Reporting Survey to Determine the Etiology of Vaccine-Induced Injury Recruiting NCT05095844
46 International GBS Outcome Study (IGOS): A Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS). Active, not recruiting NCT01582763
47 Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome: A Pilot Study Enrolling by invitation NCT04053452
48 Ultrasonographic and Electrophysiological Follow up of Patients With Guillain Barre Syndrome Before and After Treatment Not yet recruiting NCT05284786
49 A Prospective, Multi-center, Randomized Parallel Controlled Clinical Study on the Efficacy and Safety of Protein A Immunoadsorption and Intravenous Immunoglobulin in the Treatment of Guillain-Barre Syndrome Not yet recruiting NCT05114941 intravenous immunoglobulin
50 NEUROKINASE : Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases. Not yet recruiting NCT04674163

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Immunoglobulins, Intravenous

Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

Anatomical Context for Guillain-Barre Syndrome

Organs/tissues related to Guillain-Barre Syndrome:

MalaCards : Spinal Cord, Brain, Heart, Bone Marrow, Skin, T Cells, Dorsal Root Ganglion

Publications for Guillain-Barre Syndrome

Articles related to Guillain-Barre Syndrome:

(show top 50) (show all 11283)
# Title Authors PMID Year
Guillain-Barré Syndrome Following Zika Virus Infection Is Associated With a Diverse Spectrum of Peripheral Nerve Reactive Antibodies. 62 41
36411078 2023
Triggers of Guillain-Barré Syndrome: Campylobacter jejuni Predominates. 62 41
36430700 2022
Additional Steroid Therapy for Delayed Facial Palsy in Miller Fisher Syndrome. 62 41
36385049 2022
Hypocretin/orexin and narcolepsy: new basic and clinical insights. 53 62
19555382 2010
[Evaluation of myelin basic protein levels with receiver operating characteristic curves for diagnosis of multiple sclerosis]. 53 62
19246291 2009
Guillain-Barré syndrome. 53 62
16271648 2005
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. 53 62
16170091 2005
Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. 53 62
15979356 2005
Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. 53 62
14653854 2004
Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. 53 62
12676332 2003
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 53 62
11912115 2002
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. 53 62
11756606 2001
Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. 53 62
11438177 2001
Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. 53 62
11200685 2000
Anti-PMP22 antibodies in patients with inflammatory neuropathy. 53 62
10713353 2000
[Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies]. 53 62
10377820 1999
Induction of experimental autoimmune neuritis with peripheral myelin protein-22. 53 62
9798745 1998
T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. 53 62
9455979 1997
Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis. 53 62
8707926 1996
[Anti-glycoconjugate antibodies and dysglobulinemic or dysimmune peripheral neuropathies]. 53 62
8881439 1996
Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. 53 62
8583236 1995
Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. 53 62
7905957 1994
Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. 53 62
7689591 1993
T cell responses to myelin proteins in Guillain-Barré syndrome. 53 62
1279128 1992
In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes. 53 62
1718212 1991
Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. 53 62
2094193 1990
Antibodies to gangliosides and myelin proteins in Guillain-Barré syndrome. 53 62
2194427 1990
Use of functional magnetic resonance imaging to assess cognition and consciousness in severe Guillain-Barré syndrome. 62
36415610 2023
Antibodies to Glycolipids in Guillain-Barré Syndrome, Miller Fisher Syndrome and Related Autoimmune Neurological Diseases. 62
36255685 2023
Neurological Emergencies in the Intensive Care Unit. 62
36415065 2023
Identification of an N-phenylsulfonyl-2-(piperazin-1-yl)methyl-benzonitrile derivative as Zika virus entry inhibitor. 62
36417826 2023
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination. 62
36411077 2023
Unravelling the Imaging Conundrum of Rabies. 62
36451958 2022
Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. 62
35108152 2022
Complex Hallucinations in Hospitalized Rehabilitation Patients With COVID-19. 62
36277732 2022
A case of COVID-19 with multiple cranial neuropathies. 62
33372575 2022
Seizures in a patient with Guillain Barre syndrome: are antibodies disrupting the blood brain barrier? 62
35980481 2022
Assessment of neurological sequelae and new-onset symptoms in the long-term follow-up of paediatric Guillain-Barre syndrome: A longitudinal study from India. 62
36054714 2022
Discovery of dehydroandrographolide derivatives with C19 hindered ether as potent anti-ZIKV agents with inhibitory activities to MTase of ZIKV NS5. 62
36055002 2022
Neurological consequences of COVID-19. 62
36180640 2022
Notch signaling dependent monocyte conversion alleviates immune-mediated neuropathies by regulating RBP-J/NR4A1 axis. 62
36356552 2022
CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma. 62
36074313 2022
Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review. 62
36098903 2022
[Clinical and neurophysiological patterns of early presenting symptoms in acute onset chronic inflammatory demyelinating polyradiculoneuropathy]. 62
36440746 2022
Immunoglobulin Use for the Management of Painful Peripheral Neuropathy: A Systematic Review and Meta-Analysis. 62
35925489 2022
Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia. 62
36357291 2022
Identical late motor responses in early Guillain-Barré syndrome: A-waves and Repeater F-waves. 62
36453598 2022
Reversible conduction failure in acute inflammatory demyelinating polyneuropathy. 62
36329046 2022
Role of lymphocyte-related immune-inflammatory biomarkers in detecting early progression of Guillain-Barré syndrome. 62
36063751 2022
Neurological Complications Following COVID-19 Vaccination. 62
36445631 2022

Variations for Guillain-Barre Syndrome

Expression for Guillain-Barre Syndrome

Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for Guillain-Barre Syndrome

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
4 11.76 PMP22 MPZ MBP
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
16 10.99 PMP22 MPZ MBP
18 10.65 TNFRSF1A TNF

GO Terms for Guillain-Barre Syndrome

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transport vesicle membrane GO:0030658 9.72 HLA-DRB1 HLA-DQB1 HLA-DQA1
2 compact myelin GO:0043218 9.56 PMP22 MBP
3 tumor necrosis factor receptor superfamily complex GO:0002947 9.46 TNFRSF1B TNFRSF1A
4 myelin sheath GO:0043209 9.43 PMP2 MPZ MBP
5 MHC class II protein complex GO:0042613 9.1 HLA-DRB1 HLA-DQB1 HLA-DQA1

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.13 TNFRSF1B TNF MBP IL17A HLA-DRB1 HLA-DQB1
2 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 10 TNFRSF1B TNFRSF1A TNF
3 T cell receptor signaling pathway GO:0050852 9.98 MOG HLA-DRB1 HLA-DQB1 FCHO1
4 aortic valve development GO:0003176 9.81 TNFRSF1B TNFRSF1A
5 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.8 HLA-DRB1 HLA-DQB1 HLA-DQA1
6 negative regulation of extracellular matrix constituent secretion GO:0003332 9.78 TNFRSF1B TNFRSF1A
7 pulmonary valve development GO:0003177 9.76 TNFRSF1B TNFRSF1A
8 antigen processing and presentation GO:0019882 9.67 HLA-DRB1 HLA-DQB1 HLA-DQA1
9 positive regulation of apoptotic process involved in morphogenesis GO:1902339 9.67 TNFRSF1A TNFRSF1B
10 peptide antigen assembly with MHC class II protein complex GO:0002503 9.65 HLA-DRB1 HLA-DQB1 HLA-DQA1
11 immunoglobulin production involved in immunoglobulin-mediated immune response GO:0002381 9.33 HLA-DRB1 HLA-DQB1 HLA-DQA1
12 positive regulation of T cell activation GO:0050870 9.17 HLA-DRB1 HLA-DQB1 HLA-DQA1 FCHO1
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor binding GO:0043120 9.56 TNFRSF1B TNFRSF1A
2 peptide antigen binding GO:0042605 9.55 HLA-DRB1 HLA-DQB1 HLA-DQA1
3 MHC class II protein complex binding GO:0023026 9.35 HLA-DRB1 HLA-DQB1 HLA-DQA1
4 MHC class II receptor activity GO:0032395 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1

Sources for Guillain-Barre Syndrome

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....